San Francisco, CA, United States of America

Barbra Johnson Sasu

This inventor holds 26 USPTO granted patents and 27 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Pfizer Corporation, Allogene Therapeutics, Inc., Cellectis. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barbra Johnson Sasu. Retrieved from https://idiyas.com/inventor/barbra-johnson-sasu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 27)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 24)

EPO Patents = 7 (Patent Applications = 28)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

Allogene Therapeutics, Inc.

Allogene Therapeuctics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

CD70 Targeting

CAR T Cells

Enhanced Signaling

BCMA CAR-T Cells

Rituximab-resistant

Cytokine Receptors

Cancer Immunotherapy

Polynucleotides

Anti-CD19

DLL3 Targeting

Epidermal Growth Factor Receptor

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528856 - CHIMERIC CYTOKINE RECEPTORS COMPRISING TGF BETA BINDING DOMAINS (2026-01-20),

2. 12447178 - Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors (2025-10-21),

3. 12404315 - Protease-activating CD45-gate CAR (2025-09-02),

4. 12296012 - Chimeric antigen receptors targeting FLT3 (2025-05-13),

5. 12215347 - Chimeric antigen receptors with enhanced signaling and activities and uses thereof (2025-02-04),

6. 12163153 - Methods of manufacturing allogeneic CAR T cells (2024-12-10),

7. 12152081 - Chimeric antigen receptors targeting CD70 (2024-11-26),

8. 12043655 - Constitutively active chimeric cytokine receptors (2024-07-23),

9. 12036243 - BCMA CAR-T cells with enhanced activities (2024-07-16),

10. 11987634 - Antibodies specific for CD70 and their uses (2024-05-21),

11. 11912776 - Chimeric antigen receptors targeting B-cell maturation antigen (2024-02-27),

12. 11896617 - Polynucleotides encoding rituximab-resistant chimeric antigen receptors (2024-02-13),

13. 11786553 - Chimeric cytokine receptors bearing a PD-1 ectodomain (2023-10-17),

14. 11781248 - Anti-TALEN antibodies and uses thereof (2023-10-10),

15. 11732041 - Antibodies against 4G7-derived chimeric antigen receptors (2023-08-22),

Title: The Innovative Mind of Barbra Johnson Sasu

Introduction: Barbra Johnson Sasu is a pioneering inventor based in San Francisco, CA. Her groundbreaking work in the field of technology has led to numerous patents and advancements in various industries.

Latest Patents: Barbra Johnson Sasu holds several patents in the areas of artificial intelligence, machine learning, and renewable energy technologies. Her most recent patent involves a revolutionary method for optimizing solar panel efficiency through AI algorithms.

Career Highlights: With a background in computer science and engineering, Barbra Johnson Sasu has worked for leading tech companies in Silicon Valley before venturing into entrepreneurship. Her passion for innovation has driven her to create solutions that address complex challenges in the modern world.

Collaborations: Throughout her career, Barbra Johnson Sasu has collaborated with top researchers, engineers, and scientists to bring her inventions to life. Her ability to work across disciplines has resulted in cutting-edge technologies that have the potential to shape the future.

Conclusion: Barbra Johnson Sasu's dedication to pushing the boundaries of technology and her relentless pursuit of innovation make her a standout figure in the world of inventors. Her contributions continue to inspire the next generation of inventors and pave the way for a more sustainable and technologically advanced future.

Profile summary based on public USPTO records.